Answers are grounded in this paper and cite their sources.
In December 2019, the first case of patient with severe acute respiratory syndrome (SARS) caused by the novel coronavirus, SARS-CoV-2, was reported in Wuhan, Hubei Province, Central China. SARS-CoV-2 causes CoronaVirus Disease-2019 (COVID-19 or nCoV-19) disease, which rapidly spread all over the world. In response to this serious situation, on 30 January 2020, the World Health Organization (WHO) declared a global public health emergency of international concern, putting all health organizations on high alert. In mid-March 2020, WHO declared nCoV-19 a pandemic. By the end of September 2020, there were ~33.67 million confirmed cases and ~10.08 lakh deaths worldwide and the trend rising on each passing day. SARS-CoV-2 mainly infects the pulmonary system, but cause damage to other organs such as heart, kidney and intestine. Understanding the cardio-pulmonary issues underpinning of nCOV-19 pathogenesis is key to managing outcomes and mortality. SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease inhibitor TMPRSS2 for S protein priming. Alveolar cells and cardiomyocytes express ACE2 and TMPRSS2. In this Review, we summarize the current understanding of nCOV-19 pandemic from basic mechanisms to clinical perspectives, focusing on the interaction between SARS-CoV-2 and the cardio-pulmonary-immune signatures. The study provides crucial insights into the first step of SARS-CoV-2 infection, and potential targets for antiviral intervention.
No takes yet. Share an insight, caveat, or question.
Charan Reddy Kudumula (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: